🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 28202V207 (prev. 28202V108 )
- Market Cap
- Micro Cap
- IPO
- 1/8/2021
- Previous Symbol
- LWAC (changed 8/31/2021)
- Previous Name
- Fantina Holdings Ltd.
Business: eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs known as selective translation regulator inhibitors (STRIs).
Notes: January 9, 2024 -- eFFECTOR Therapeutics, Inc. (the “Company”) filed an amendment (the “Amendment”) to its amended and restated certificate of incorporation to effectuate a reverse stock split of the Company’s common stock, par value $0.0001per share (“Common Stock”). Pursuant to the Amendment, at the effective time of 12:01 a.m. Eastern Time on January 12, 2024, each 25 shares of Common Stock issued and outstanding will be combined into one validly issued, fully paid and non-assessable share of Common Stock (the “Reverse Stock Split”). The par value per share remains the same. Trading of the Common Stock on a Reverse Stock Split-adjusted basis will begin at the opening of trading on the Nasdaq Capital Market on January 12, 2024. The new CUSIP number for the Common Stock following the Reverse Stock Split is 28202V207.
Company Contact
- CEO
- Steve Worland
- CFO
- Mike Byrnes
- Headquarters
- 142 North Cedros Avenue, Suite B, Solana Beach, CA 92075
- Phone
- 858-422-4300
- Investor Relations
- Stephanie Carrington, Westwicke · 646-277-1282 · Stephanie.Carrington@westwicke.com